<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320646">
  <stage>Registered</stage>
  <submitdate>15/10/2009</submitdate>
  <approvaldate>16/10/2009</approvaldate>
  <actrnumber>ACTRN12609000899246</actrnumber>
  <trial_identification>
    <studytitle>The Effects of Dobutamine and Levosimendan in High Risk Cardiac Surgery Patients</studytitle>
    <scientifictitle>The Effects of Dobutamine and Levosimendan in High Risk Cardiac Surgery Patients</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cardiac</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will recieve intravenous Levosimendan 0.1-0.2 mcg/kg/min for 24hrs</interventions>
    <comparator>Dobutamine 2.5mcg/kg/min for 24hrs</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To detect a 40 % increase in Cardiac Index on day 5 post cardiac surgery from baseline</outcome>
      <timepoint>Days 1 and 5</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All cause mortality and 180 day mortality</outcome>
      <timepoint>measured from baseline through to 180 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients presenting for Coronary artery bypass grafting or valve surgery or both.Documented pre operative  left ventricular ejection fraction = 30 % or moderate to severe Left Ventricular Failure (echo finding).Willingness to give written informed consent and willingness to participate  and comply with the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who have received Levosimendan in the past 2 weeks.Patients who are moribund and not expected to survive. Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.Patients with established renal failure ( Glomerular Filtration Rate &lt;30 % +/- dialysis ).Patients who weigh &gt;150 kg.Patients aged &lt;18 years.Patients undergoing salvage surgery.Patients with a known or suspected infection and who also have 2 or more systemic inflammatory response syndrome criteria who are on high dose vasopressors (High dose vasopressors  Noradrenaline &gt;0.2 mcg/kg/min or Dobutamine &gt;10 mcg/kg/min).Patients with cardiogenic shock due to an untreated mechanical cause ie pulmonary embolism, tamponade, acute valve disease . Patients with a known or suspected allergy to the study drugs.Cardiogenic shock unresponsive to high dose vasopressors (Noradrenaline &gt;0.2 mcg/kg/min or Dobutamine &gt;10 mcg/kg/min) persistant mean arterial pressure&lt; 60 mmHG or systolic blood pressure &lt; 80 mmHg.Congenital Heart disease or acquired structural cardiac defect eg ventricular septal defect. Administration of Milronone within 24 hours before the start of Levosimendan infusion.Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
History of Torsades de pointes.Uncorrected serum potassium levels &lt;3.5mmols/L or &gt;4.5mmols/L.Patients who appear to be responding adequately to standard therapy
.Severe obstruction of ventricular outflow tracts such as haemodynamically significant uncorrected primary valve disease and restricted or hypertrophic cardiomyopathy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomised  sealed envelopes</concealment>
    <sequence>Random computer generation in blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/12/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Intensive Care Research Fund</primarysponsorname>
    <primarysponsoraddress>Prince of Wales Hospital, Barker Street, Randwick, 2031 NSW</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Intensive Care Research Fund</fundingname>
      <fundingaddress>Prince of Wales Hospital, Barker Street, Randwick, 2031 NSW</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Single centre double blinded randomised trial comparing Levosimendan with Dobutamine in high risk cardiac surgery patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital Ethics</ethicname>
      <ethicaddress>Prince of Wales Hospital, Edmund Blacket Building, Avoca Street, Randwick, 2031, NSW</ethicaddress>
      <ethicapprovaldate>9/09/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>23/01/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Yahya Shehabi</name>
      <address>Prince of Wales Hospital
Adult Intensive Care Unit
Barker Street
Randwick 2031 NSW</address>
      <phone>+612 93824720</phone>
      <fax>+612 93824748</fax>
      <email>Yahya.Shehabi@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Yahya Shehabi</name>
      <address>Prince of Wales Hospital
Adult Intensive Care Unit
Barker Street
Randwick 2031 NSW</address>
      <phone>+612 93824720</phone>
      <fax>+612 93824748</fax>
      <email>Yahya.Shehabi@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Frances Bass</name>
      <address>Prince of Wales Hospital
Adult Intensive Care Unit
Barker Street
Randwick 2031 NSW</address>
      <phone>+612 93824720</phone>
      <fax>+612 93824748</fax>
      <email>Frances.Bass@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>